mRNA-based Influenza B vaccine (Acuitas Therapeutics/University of Pennsylvania/Icahn School of Medicine at Mount Sinai/Biological Research Center)

N/A

Report date: 2025/12/18 17:46:46

Base Information

Drug NamemRNA-based Influenza B vaccine (Acuitas Therapeutics/University of Pennsylvania/Icahn School of Medicine at Mount Sinai/Biological Research Center)
Drug Alias Namelipid nanoparticle-encapsulated nucleoside-modified mRNA vaccine (Acuitas Therapeutics/University of Pennsylvania/Icahn School of Medicine at Mount Sinai/Biological Research Center)pentavalent nucleoside-modified mRNA vaccine (Acuitas Therapeutics/University of Pennsylvania/Icahn School of Medicine at Mount Sinai/Biological Research Center)
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionInfluenza virus hemagglutinin glycoproteins modulators
TargetsInfluenza virus hemagglutinin glycoproteins
Therapy Area/IndicationsInfluenza B virus infection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesHungary
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesBiological Research Center of the Hungarian Academy of SciencesAcuitas Therapeutics IncIcahn School Of Medicine At Mount Sinai +[4] 
Inactive CompaniesN/A
Active IndicationsInfluenza B virus infection
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A